Pharmaceutical Grade API Sorafenib Tosylate
You are here: Home » Products » API » Anti-cancer APIS » Sorafenib Tosylate » Pharmaceutical Grade API Sorafenib Tosylate


Pharmaceutical Grade API Sorafenib Tosylate

CAS No.:475207-59-1
Type:Pharmaceutical API
Appearance:White or slightly yellowish or brownish powder
Certificate:GMP, COPP, WC, DMF, CEP
Shelf Life:2 years
Quality Standard:CP, EP, USP
Chemical Name:4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino] phenoxy]-N-methylpyridine-2-carboxamide;4- methylbenzenesulfonic acid
facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
whatsapp sharing button
sharethis sharing button

Product Description

Sorafenib exerts its therapeutic effects by inhibiting multiple kinases involved in tumor growth and angiogenesis. As a multi-kinase inhibitor, it interferes with signaling pathways crucial for cancer cell proliferation and the formation of new blood vessels that supply tumors. The primary targets of Sorafenib include Raf kinases, vascular endothelial growth factor receptors (VEGFRs), and platelet-derived growth factor receptors (PDGFRs). By disrupting these pathways, Sorafenib aims to slow down cancer progression and impede the development of new blood vessels that support tumor growth.


  1. Hepatocellular Carcinoma (HCC):Sorafenib is a first-line treatment for advanced hepatocellular carcinoma, the most common form of liver cancer. Its use in HCC is supported by clinical trials demonstrating extended overall survival and delayed disease progression.

  2. Renal Cell Carcinoma (RCC):Sorafenib is also indicated for the treatment of advanced renal cell carcinoma, a type of kidney cancer. In this setting, it has shown efficacy in slowing tumor growth and improving progression-free survival.

  3. Thyroid Carcinoma:Sorafenib is approved for the treatment of advanced differentiated thyroid carcinoma that is refractory to radioactive iodine treatment. It has been found to have a positive impact on progression-free survival in this patient population.


1.00kg/bag, 5.00kg/bag, 10.00kg/bag, or according to customer’s requirements.

Related Products

Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.



Copyright © 2023 Shandong Loncom Pharmaceutical Co., Ltd. All Rights Reserved. Sitemap | Privacy Policy
Supported by
Contact Us